Clorox Co (CLX) Q2 Earnings: EPS Surges to $1.54, Revenue Hits $1.69 Billion, Exceeding Estimates

GuruFocus
04 Feb

On February 3, 2025, Clorox Co (CLX, Financial) released its 8-K filing detailing the financial results for the second quarter of fiscal year 2025, which ended on December 31, 2024. The company reported net sales of $1.69 billion, surpassing the analyst estimate of $1.627 billion, despite a 15% year-over-year decrease. This decline was primarily attributed to the aftermath of the August 2023 cyberattack and the divestitures of the Better Health Vitamins, Minerals and Supplements (VMS) and Argentina businesses.

Company Overview

Since its inception over a century ago, Clorox Co (CLX, Financial) has established itself as a prominent player in the consumer products sector. The company's diverse portfolio includes well-known brands such as Clorox, Liquid-Plumr, Pine-Sol, Kingsford, Fresh Step, Glad, Hidden Valley, Brita, and Burt's Bees, with nearly 85% of its sales generated in the United States.

Performance and Challenges

Clorox Co (CLX, Financial) faced significant challenges in the second quarter, including a 15% decrease in net sales compared to the previous year. This was largely due to the impact of the cyberattack and strategic divestitures. Despite these hurdles, the company achieved a gross margin increase of 30 basis points to 43.8%, driven by cost savings and benefits from divestitures.

Financial Achievements

The company reported a diluted net earnings per share (EPS) of $1.54, a substantial 105% increase from the previous year's $0.75. However, the adjusted EPS decreased by 28% to $1.55, primarily due to lower net sales. Clorox Co (CLX, Financial) also reported a significant increase in year-to-date net cash provided by operations, which rose by 132% to $401 million.

Key Financial Metrics

Clorox Co (CLX, Financial) demonstrated resilience in its financial performance, with notable achievements in cost management and operational efficiency. The company achieved its ninth consecutive quarter of gross margin expansion, supported by strong cost-saving measures. Additionally, Clorox Co (CLX) grew its market share in seven of its eight categories, highlighting the effectiveness of its demand creation strategies.

Segment Performance

Segment Net Sales Growth Adjusted EBIT Change
Health and Wellness -13% -25%
Household -11% -48%
Lifestyle -16% -36%
International -12% -34%

Analysis and Outlook

Clorox Co (CLX, Financial) has shown resilience in navigating a challenging environment, with strategic divestitures and cost-saving initiatives contributing to its financial stability. The company's decision to acquire P&G's 20% interest in the Glad joint venture aligns with its IGNITE strategy, aiming for streamlined operations and enhanced digital capabilities. Clorox Co (CLX) remains focused on delivering long-term, profitable growth through innovation and superior value offerings.

“We achieved better-than-expected results across sales, margin, and EPS in the second quarter due to our strong demand creation plans, which also supported our share growth,” said Chair and CEO Linda Rendle.

For more detailed financial information, visit Clorox Co (CLX, Financial)'s Quarterly Results.

Explore the complete 8-K earnings release (here) from Clorox Co for further details.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10